Cancer Research Meeting Calendar  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, W.
Right arrow Articles by Phillips, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, W.
Right arrow Articles by Phillips, D. H.
[Cancer Research 60, 2887-2891, June 1, 2000]
© 2000 American Association for Cancer Research


Carcinogenesis

Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction1

Warren Davis2, Alan Hewer, Krzysztof M. Rajkowski, Walter Meinl, Hansruedi Glatt and David H. Phillips3

Institute of Cancer Research, Haddow Laboratories, Surrey SM2 5NG, United Kingdom [W. D., A. H., D. H. P.]; INSERM U488, 80 rue de Général Leclerc, Hôpital de Bicêtre, F-94276 Le Kremlin-Bicêtre, France [K. M. R.]; and Department of Toxicology, German Institute of Human Nutrition, D-14558 Potsdam-Rehbrücke, Germany [W. M., H. R. G.]

Previous work has indicated that metabolic activation of tamoxifen in rat liver cells involves cytochrome P450-mediated {alpha}-hydroxylation, followed by sulfate ester formation, mediated by hydroxysteroid sulfotransferase a (rHSTa), a member of the SULT2A subfamily, which efficiently metabolizes dehydroepiandrosterone. Because it is known that the expression of rHSTa and other SULT2A forms is substantially higher in female rats than in males, it might be predicted that tamoxifen would be a more potent liver carcinogen in females than in males. Yet tamoxifen has been shown to be equipotent in both sexes. To investigate this paradox, primary cultures of hepatocytes were prepared from Fischer F-344 rats and treated with tamoxifen (10 µM) or {alpha}-hydroxytamoxifen (1 µM). Rats were also treated with tamoxifen daily by gavage (0.12 mmol/kg/day) for up to 14 days. DNA was isolated from hepatocytes and liver and analyzed by 32P-postlabeling. Liver cytosol fractions were prepared and analyzed for dehydroepiandrosterone sulfotransferase activity and SULT2A protein levels. In tamoxifen-treated hepatocytes and after a single dose of tamoxifen in vivo, DNA adduct formation in male cells was significantly lower than in female cells, 11- and 6-fold, respectively. However, with increasing daily doses of rats with tamoxifen, the adduct level in males increased to a level 89% of that in females by 14 days. Dehydroepiandrosterone sulfotransferase activity in male rat liver cytosols was only 17% of the activity of female cytosols after one dose of tamoxifen but 64% after 14 days of exposure to the compound. This increase in activity correlated with increases in the levels of SULT2A protein, detected by Western blotting. Western blotting did not allow the unambiguous identification of the induced SULT2A form(s). However, by using a specific reverse transcriptase/PCR technique, it was found that it was primarily rHSTa that was induced. Thus, after prolonged exposure to tamoxifen, DNA adduct formation and rHSTa expression in males are significantly closer to the levels in females than they are after initial exposure. These changes explain the similar susceptibility of male and female rats to tamoxifen carcinogenesis.




This article has been cited by other articles:


Home page
MutagenesisHome page
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt
Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment
Mutagenesis, July 1, 2005; 20(4): 297 - 303.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier
Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods
Mutagenesis, March 1, 2005; 20(2): 115 - 124.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H.-L. Fang, M. Abdolalipour, Z. Duanmu, J. R. Smigelski, A. Weckle, T. A. Kocarek, and M. Runge-Morris
REGULATION OF GLUCOCORTICOID-INDUCIBLE HYDROXYSTEROID SULFOTRANSFERASE (SULT2A-40/41) GENE TRANSCRIPTION IN PRIMARY CULTURED RAT HEPATOCYTES: ROLE OF CCAAT/ENHANCER-BINDING PROTEIN LIVER-ENRICHED TRANSCRIPTION FACTORS
Drug Metab. Dispos., January 1, 2005; 33(1): 147 - 156.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques
Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans
J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Maiti and G. Chen
Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine
Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa
Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats
Carcinogenesis, March 1, 2002; 23(3): 491 - 498.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.